



石四藥集團有限公司

SSY Group Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

2017
Interim Report

CORPORATE INFORMATION

STOCK CODE

2005

EXECUTIVE DIRECTORS

Mr. Qu Jiguang (*Chairman*)
Mr. Wang Xianjun
Mr. Su Xuejun

INDEPENDENT NON-EXECUTIVE DIRECTORS

Mr. Wang Yibing
Mr. Leung Chong Shun
Mr. Chow Kwok Wai

COMPANY SECRETARY

Mr. Chow Hing Yeung

REGISTERED OFFICE

Cricket Square, Hutchins Drive
P.O. Box 2681, Grand Cayman
KY1-1111, Cayman Islands

HEAD OFFICE AND PRINCIPAL PLACE OF BUSINESS IN HONG KONG

Rooms 4902-03, 49th Floor
Central Plaza, 18 Harbour Road
Wanchai, Hong Kong

AUTHORISED REPRESENTATIVES

Mr. Wang Xianjun
Mr. Chow Hing Yeung

AUDIT COMMITTEE

Mr. Chow Kwok Wai (*Chairman*)
Mr. Wang Yibing
Mr. Leung Chong Shun

REMUNERATION COMMITTEE

Mr. Leung Chong Shun (*Chairman*)
Mr. Wang Yibing
Mr. Chow Kwok Wai

NOMINATION COMMITTEE

Mr. Wang Yibing (*Chairman*)
Mr. Leung Chong Shun
Mr. Chow Kwok Wai

PRINCIPAL SHARE REGISTRAR AND TRANSFER OFFICE

SMP Partners (Cayman) Limited
Royal Bank House - 3rd Floor
24 Shedden Road
P.O. Box 1586, Grand Cayman
KY1-1110, Cayman Islands

HONG KONG BRANCH SHARE REGISTRAR AND TRANSFER OFFICE

Computershare Hong Kong Investor
Services Limited
17M Floor, Hopewell Centre
183 Queen's Road East
Wanchai, Hong Kong

PRINCIPAL BANKERS

Agricultural Bank of China
Bank of China
Bank of Communications
Bank of Hebei
BNP Paribas Hong Kong Branch
China CITIC Bank
China CITIC Bank International
Hang Seng Bank
Hongkong and Shanghai Banking
Corporation
Industrial and Commercial Bank of China

LEGAL ADVISER TO THE COMPANY AS TO HONG KONG LAW

DLA Piper Hong Kong

AUDITOR

KPMG

WEBSITE

<http://www.ssygroup.com.hk>

CHAIRMAN'S STATEMENT

On behalf of the board of directors (the "Board") of SSY Group Limited (the "Company"), I hereby present the unaudited interim results of the Company and its subsidiaries (the "Group") for the six months ended 30 June 2017.

I. RESULTS AND DIVIDEND DISTRIBUTION

During the first half of the year, the pharmaceutical industry in the PRC showed a steady growth as a whole that gradual implementation of various healthcare reform policies drove the industry consolidation. In the infusion solutions industry, the integration effect on the industry brought by national policies on restricting infusion solutions was obvious. The Company seized the opportunities by taking our own advantages in scale, quality and brand. Also, we strengthened market penetration in traditional market and, at the same time, tapped into new markets to maintain our development status at the leading position in the industry.

During the first half of the year, the Group achieved a revenue of HK\$1,325 million (or approximately RMB1,169 million), representing an increase of 19.5% (or approximately 25.2% in RMB) compared to the corresponding period of last year, and the gross profit margin increased by 5.3 percentage point. The net profit was HK\$288 million (or approximately RMB254 million), representing an increase of 36.9% (or approximately 43.4% in RMB) compared to the corresponding period of last year.

The Directors resolved to pay an interim dividend of HK3 cents per share for the six months ended 30 June 2017 (amounting to a total of approximately HK\$85,199,000) on 21 September 2017 to the shareholders named in the register of members of the Company on 8 September 2017.

II. BUSINESS REVIEW

(I) Sales of Products

During the first half of the year, the Company's products further widened its market and stepped up the development in new market such that certain new provinces had become our major markets. The Company gradually evolved from Northern China-based regional market into national market. With the product mix optimisation and the increase in the proportion of high price and high gross margin products, the volume growth of non-PVC and upright soft bags was significant, bringing the reasonable increase in the average selling price and gross profit margin of our products.

During the first half of the year, sales of intravenous infusion solutions reached 627 million bags/bottles, representing an increase of 16.3% compared with the same period last year. Sales of soft bag infusion, our major product, amounted to 332 million bags, representing a corresponding increase of 25.0%, in which the sales of upright soft bags reached 93 million bags, representing a corresponding increase of 35.2%, which was among the best in the industry and our advantage in product scale was further enhanced.

Our international export business maintained a rapid growth. During the first half of 2017, our exports achieved HK\$50.48 million, an increase of 30.2% compared with the same period last year. We also passed the quality inspection of our French customers, IDA quality inspection and the GMP certification of Ethiopian Ministry of Health. Currently, the Group has 66 registered product specifications for exporting to 78 countries or regions.

In respect of medical materials, the sales volume of rubber stoppers and the production volume of infusion films had a corresponding increase of 25% and 67% respectively during the first half of the year. While our existing market share of rubber stopper was being consolidated, we leveraged on our technological advantages, kept fostering the market expansion on our new products, such as high-end hemostix rubber stopper and disposable rubber stopper, to create profit growth point for the medical materials business of the Company with high-tech and high value-added products.

(II) Research and Development of New Products

The research and development for new products achieved a satisfactory result in the first half of the year. The Company obtained drug production permits for amino acid injection compound in soft bag package (18AA), sodium bicarbonate injection in plastic bottle package and tinidazole and sodium chloride injection in upright soft bag package; added new types of polypropylene ampoules liquid injections containing glucose injection and sterile water for injection with product specifications of 5ml, 10ml and 20ml. For consistency reviews, the Company completed the out-of-body evaluation and bioequivalence clinical trials for fluconazole tablets, and commenced the related bioequivalence clinical studies. In addition, we completed the bioequivalence clinical studies of levamlodipine beaylate and cefdinir capsules, in accordance with the original research applied for their productions. Meanwhile, in response to the national policy, the Company completed the research of sodium bicarbonate injection for children and levamlodipine beaylate applied for its production.

The radiation resistant and sterilised hemostix rubber stopper satisfied the needs for radiation resistant and sterilised hemostix products and filled the gaps in the domestic market. The new-developed semi-coated rubber stopper solved the compatibility issue between cancer drugs and rubber stopper, which can be used to replace the imported rubber stopper. Our self-developed disposable sterilised rubber stopper is suitable for foreign markets and is registered in the United States successfully.

Currently, the Group has 161 projects under research and development, 54 of which have been submitted for production registration evaluation. The innovative results were increasingly rich when the support from research and development was enhanced. In the first half of the year, the Group obtained 7 patents including 5 invention patents and 2 practical new patents; and applied for 6 patents including 3 invention patents and 3 practical new patents, which represented fruitful results of intellectual rights and provided sufficient support for the sustainable development of the Group.

III. PROSPECTS FOR DEVELOPMENT

Looking ahead for the second half of the year, the intravenous infusion solutions industry will regain its momentum after the industry consolidation led by national policies such as restriction on infusion solutions. The consolidation effect will continue to be revealed in the intravenous infusion solutions industry. The Company will grasp the opportunities to strengthen our two driving forces: marketing and research & development, to solidify and expand the Company's leading position in the intravenous infusion solutions industry.

In the second half of the year, the Group will make use of its own advantages over the scale and brand name for broadening the market of products, optimising product mix, enhancing production efficiency, introducing lean management, boosting the profitability of intravenous infusion solution products and realising the steady growth in both revenue and profit.

The Company is actively looking for acquisitions and mergers opportunities in pharmaceutical industry. As mergers and acquisitions will become a general trend in the industry due to intense market competition and national policies, the Company will actively explore acquisitions and mergers opportunities on the foundation of its competitive edges, with an aim to strengthening the market and product positions of the Company.

In respect of new product development, the Company expects to complete the process of national technology authentication of 32 projects (including peritoneal dialysis solution) in the second half of the year to obtain the production permits as soon as possible once supplementing documents are completed. The Company will also complete applications for production of 6 items, including new amino acid and glucose injection in dual-chamber bag and salbutamol sulfate aerosol complete the bioequivalence clinical studies in accordance with the original research on 3 projects including the statins rosuvastatin calcium tablets for reducing blood lipid and applied for their production; complete the bioequivalence

clinical record on 8 projects including prucalopride succinate tablets: the first drug for curing female constipation. For consistency reviews, the Company will complete the separate review of eanitidine hydrochloride capsules and cefalexin capsules. The clinical works on Lacosamide (previous Type 3.1 new drug) is on-going to strive for completing the application for production next year.

In the second half year of 2017, it is expected that 11 production permits will be obtained for new products, including raw material drugs tenofovir disoproxil fumarate tablets for the treatment of AIDS and hepatitis B, hemofiltration basic solution, hydroxyethyl starch 130 sodium chloride injection and hydroxyethyl starch 200/0.5 sodium chloride injection. It is also expected that the production permits of ambroxol hydrochloride injection in upright soft bags package will be increased. We will strive to obtain the production permits for bulk pharmaceuticals and preparations of several generic drugs in 2018.

By speeding up the development of National and Local Joint Engineering Laboratory project, propelling the establishment of national enterprise technology centre proactively, using various existing research and development platforms and cooperating with domestic tertiary schools and scientific research institutions, we will focus on creating advantages on development of high-end productions technology for microspheres, liposomes, nanocrystals, etc. In addition, the growth of the Group is fully supported by the development of sustained-release tablets for new psychiatric drugs and better target technology for anti-tumour drugs.

In respect of the development of medical materials, we will keep a close eye to the forefront of industry development, continuously develop new types of hemostix rubber stopper and aim to achieve a break-through in exporting to foreign market. Further, we will put a great effort into the market development of rubber stopper for biological products. We will endeavour to obtain registration permits for rubber stopper used for pen-type syringe and pre-filled syringe in

the second half of the year. By increasing effort on technological changes, the Company will upgrade the comprehensive supporting function of infusion films product by the technological innovation of adding UV printing on infusion films production lines. We will achieve the upgrade and modification of medical rubber stopper production lines. Leveraging on equipment transformation and automation level enhancement, Jiangsu Best will be built as an excellent medical materials production base in the country to satisfy and adapt to higher requirement of packaging materials for pharmaceuticals.

We are full of confidence on the future development of the Company. Leveraging on the competitive edges on our scale, quality and lean management in the industry, our leading position in the industry of infusion solution products will be further maintained in this challenging market. We are committed to bringing satisfactory return to our investors.

I would like to take this opportunity to express our gratitude to our investors and all staff in the Group for their support to the development of the Group.

Qu Jiguang
Chairman

Hong Kong, 23 August 2017

MANAGEMENT DISCUSSION AND ANALYSIS

BUSINESS REVIEW

SSY Group Limited (the “Company”) and its subsidiaries (together, the “Group”) are principally engaged in the research, development, manufacturing and selling of a wide range of pharmaceutical products, which includes finished medicines of mainly intravenous infusion solution to hospitals and distributors, bulk pharmaceuticals and medical materials. The Group has manufacturing plants in Hebei Province and Jiangsu Province, the People’s Republic of China (the “PRC”), and sells to customers mainly in the PRC.

For the six months ended 30 June 2017, the review on the Group’s business performance and financial performance are contained in the Chairman’s statement under section headed “BUSINESS REVIEW” and in this Management Discussion and Analysis under section headed “FINANCIAL PERFORMANCE REVIEW” respectively. The future development in the Group’s business is discussed in the Chairman’s statement under section headed “PROSPECTS FOR DEVELOPMENT”.

FINANCIAL PERFORMANCE REVIEW
REVENUE

	For the six months ended 30 June				
	2017		2016		Increase/ (decrease) %
	Revenue HK\$'000	Percentage of revenue %	Revenue HK\$'000	Percentage of revenue %	
Intravenous infusion solution and others	1,261,165	95.2	1,036,716	93.5	21.6
(Including: Non-PVC soft bag & upright soft bag infusion solution	812,760	61.3	613,497	55.3	32.5
PP plastic bottle infusion solution	257,181	19.4	239,838	21.6	7.2
Glass bottle infusion solution	117,437	8.9	110,706	10.0	6.1
Others)	73,787	5.6	72,675	6.6	1.5
Medical materials	64,172	4.8	72,396	6.5	(11.4)
Total	1,325,337	100	1,109,112	100	19.5

The Group's intravenous infusion solution products are mainly manufactured and sold by Shijiazhuang No. 4 Pharmaceutical Co., Ltd. ("Shijiazhuang No. 4 Pharma"), a wholly owned subsidiary. There are different forms of packing in intravenous infusion products including Non-PVC Soft Bag, Upright Soft Bag, PP Plastic Bottle and Glass Bottle. The Group's medical materials are mainly manufactured and sold by Jiangsu Best New Medical Material Co., Ltd. ("Jiangsu Best"), which was also a wholly owned subsidiary in the Group.

Majority of the Group's sales are conducted in the PRC and are denominated in Renminbi ("RMB"), which depreciated by approximately 4.6% when translated into Hong Kong dollars ("HK\$") for the six months ended 30 June 2017 as compared with that for corresponding period of last year. Nevertheless, revenue of the Group for the six months ended 30 June 2017 increased by 19.5% from HK\$1,109,112,000 in corresponding period of last year to HK\$1,325,337,000. Among which, revenue from intravenous infusion solution accounted for HK\$1,187,378,000 (30 June 2016: HK\$964,042,000), representing an increase of 23.2% as compared with corresponding period of last year. Among which, revenue from Non-PVC Soft Bag and Upright Soft Bag Infusion Solution were HK\$666,453,000 and HK\$146,307,000 respectively, totalling HK\$812,760,000, an increase of 32.5% as compared with corresponding period of last year and accounted for 68.4% of revenue from intravenous infusion solution; revenue from PP Plastic Bottle Infusion Solution was HK\$257,181,000 an increase of 7.2% as compared with corresponding period of last year and accounted for 21.7% of revenue from intravenous infusion solution; revenue from Glass Bottle Infusion Solution was HK\$117,437,000, an increase of 6.1% as compared with corresponding period of last year and accounted for 9.9% of revenue from intravenous infusion solution.

With the increasing demand in the high quality intravenous infusion solution products in the PRC, the Group will keep focusing its production in Non-PVC Soft Bag and Upright Soft Bag Infusion Solution.

COST OF SALES

The Group's cost of sales increased by 6.8% to HK\$597,206,000 for the six months ended 30 June 2017 as compared to the corresponding period last year of HK\$559,039,000. The cost of direct materials, direct labour and other costs represented approximately 54%, 14% and 32% of the total cost of sales respectively, while their comparative percentages for the corresponding period last year were 53%, 15% and 32% respectively.

GROSS PROFIT MARGIN

For the six months ended 30 June 2017, the Group recorded a total gross profit of HK\$728,131,000 (30 June 2016: HK\$550,073,000). Overall gross profit margin increased by 5.3 percentage point to 54.9% for the six months ended 30 June 2017, from 49.6% for the corresponding period last year. The increase of gross profit margin was mainly due to a better product mix from products with higher profit margins and the Group's continuous cost control measures.

OTHER NET INCOME

For the six months ended 30 June 2017, the Group's other net income reduced to approximately HK\$2,511,000 (30 June 2016: HK\$46,779,000) due to a smaller sum of government grants.

SELLING AND DISTRIBUTION COSTS

For the six months ended 30 June 2017, selling and distribution costs amounted to approximately HK\$233,594,000 (30 June 2016: HK\$157,257,000), which mainly consisted of transportation cost of approximately HK\$161,107,000 (30 June 2016: HK\$124,021,000), advertising expenses of approximately HK\$22,051,000 (30 June 2016: HK\$1,851,000), salary expenses for sales and marketing staff of approximately HK\$18,678,000 (30 June 2016: HK\$12,478,400) as well as travelling and other disbursements of approximately HK\$13,406,000 (30 June 2016: HK\$9,797,000).

Selling and distribution expenses increased by 48.5% for the six months ended 30 June 2017 as compared with that of the corresponding period last year mainly due to increases in transportation cost, advertising expenses as well as salary expenses of sales and marketing staff as a result of an expanded sales coverage.

GENERAL AND ADMINISTRATIVE EXPENSES

For the six months ended 30 June 2017, general and administrative expenses was approximately HK\$121,755,000 (30 June 2016: HK\$150,209,000) which mainly comprised of salaries expenses for the administrative staff of approximately HK\$50,949,000 (30 June 2016: HK\$47,799,000) as well as depreciation and amortisation expenses of approximately HK\$36,662,000 (30 June 2016: HK\$32,291,000).

The decrease of 18.9% in general and administrative expense as compared to that of the corresponding period last year was mainly due to the absence of expense for grant of options during the six months ended 30 June 2017, whereas there was a one-off expense of approximately HK\$26,686,000 incurred in the corresponding period last year.

PROFIT FROM OPERATIONS

For the six months ended 30 June 2017, the Group's profit from operations amounted to HK\$375,293,000, representing an increase of 29.7% as compared to HK\$289,386,000 of the corresponding period last year, with operating profit margin (defined as profit from operations divided by total revenue) increased to 28.3% as compared to 26.1% of the corresponding period last year mainly due to a better product mix from products with higher profit margins.

FINANCE COSTS

The Group's finance costs amounted to HK\$23,175,000 for the six months ended 30 June 2017 (30 June 2016: HK\$27,286,000), which are mainly related to bank borrowings. The decrease in finance costs by 15.1% was mainly due to the decrease in average bank loan interest rate as compared to the corresponding period last year.

INCOME TAX EXPENSE

Shijiazhuang No. 4 Pharma, Jiangsu Best and Hebei Guolong Pharmaceutical Co., Ltd. were qualified as the High and New Technology Enterprise and entitled to a 15% preferential Mainland China Corporate Income Tax ("CIT") rate in both 2017 and 2016. For the six months ended 30 June 2017, the income tax expense increased by 27.3% to HK\$65,630,000 (30 June 2016: HK\$51,567,000) mainly due to a higher profit before taxation of the Group as compared to the corresponding period last year.

PROFIT ATTRIBUTABLE TO EQUITY SHAREHOLDERS

The profit attributable to equity shareholders of the Company for the six months ended 30 June 2017 increased by 36.9% to HK\$288,016,000 (30 June 2016: HK\$210,428,000) and the net profit margin (defined as profit attributable to equity shareholders of the Company for the period divided by total revenue) increased to 21.7% from 19.0% for the corresponding period last year.

INTERIM DIVIDEND

The Directors resolved to pay on 21 September 2017 an interim dividend of HK3 cents per share (amounting to a total of approximately HK\$85,199,000) for the six months ended 30 June 2017 (30 June 2016: HK2.5 cents per share) to the shareholders named in the register of members of the Company on 8 September 2017.

LIQUIDITY, FINANCIAL RESOURCES AND CAPITAL STRUCTURE

The Group primarily finances its working capital and other capital requirements by net cash generated from operating activities and resorts to external financing including both long-term and short-term bank borrowings from time to time in case the projected operating cash flow is insufficient to meet the capital requirements.

As at 30 June 2017, the cash and cash equivalents aggregated to HK\$469,950,000 (31 December 2016: HK\$447,036,000), mostly are denominated in RMB.

As at 30 June 2017, the carrying amounts of the borrowings amounted to HK\$1,646,508,000 (31 December 2016: HK\$1,567,863,000), of which HK\$809,457,000 (31 December 2016: HK\$758,690,000) and HK\$837,051,000 (31 December 2016: HK\$809,173,000) are denominated in RMB and Hong Kong dollars respectively.

Gearing ratio (defined as bank borrowings less cash and cash equivalents divided by total capital less non-controlling interests) slightly decreased from 29.5% as at 31 December 2016 to 28.3% as at 30 June 2017 mainly due to increase in the Group's net asset value as at 30 June 2017 as compared to 31 December 2016.

Current ratio (defined as current assets divided by current liabilities) slightly decreased from 1.53 as at 31 December 2016 to 1.42 as at 30 June 2017.

EMPLOYEES AND REMUNERATION POLICY

As at 30 June 2017, the Group had approximately 3,500 employees, most of whom were based in the PRC. The number of workers employed by the Group varies from time to time depending on its needs. The remuneration policy of employees other than executive Directors and senior management is based on industry practice and is periodically reviewed by executive Directors or senior management. Apart from social insurance and in-house training programmes, discretionary bonuses and share options may be awarded to employees according to the assessment of individual performance.

The remuneration policy of executive Directors and senior management are reviewed and recommended for the Board's approval by the Remuneration Committee. The remuneration package is reviewed with reference to the Board's corporate goals and objectives, prevailing market practice, duties and responsibilities of the individual executive Director or senior management and his/her contribution to the Group.

The total remuneration cost incurred by the Group for the six months ended 30 June 2017 was approximately HK\$152,416,000 (30 June 2016: HK\$171,965,000).

CHARGE ON ASSETS

As at 30 June 2017, the Group's land use right with carrying amount of HK\$19,552,000 (31 December 2016: HK\$19,241,000) and the Group's property, plant and equipments with carrying amount of HK\$28,041,000 (31 December 2016: HK\$28,979,000) were pledged as collateral for the Group's borrowings.

FOREIGN EXCHANGE RISK

Majority of the Group's businesses are operated in the PRC and are denominated in RMB. Except for the foreign currency translation risk arising from the translation into Hong Kong dollars for the financial statements of subsidiaries with the functional currencies of RMB, the Group does not expect any materially adverse effects of the exchange rate fluctuation. Hence, no financial instrument for hedging was employed. Nevertheless, the Group is closely monitoring the financial market and would consider appropriate measures if required.

As at the following dates, the exchange rates of converting Hong Kong dollars into RMB (as calculated in Hong Kong dollars) were:

1 January 2016	0.83778
30 June 2016	0.85467
1 January 2017	0.89451
30 June 2017	0.86792

MATERIAL ACQUISITIONS AND DISPOSALS

There was no material acquisition or disposal of subsidiaries or associates during the six months ended 30 June 2017.

CONTINGENT LIABILITIES

As at 30 June 2017, the Group did not have any significant contingent liabilities.

PURCHASE, SALE OR REDEMPTION OF SECURITIES

Neither the Company nor any of its subsidiaries has redeemed, purchased or sold any of the Company's listed securities for the six months ended 30 June 2017.

SHARE OPTION SCHEME

As approved by an ordinary resolution passed by the shareholders at the Extraordinary General Meeting held on 20 September 2012, the Board had terminated the old share option scheme adopted on 16 October 2005 and adopted the existing share option scheme ("Share Option Scheme").

Share Option Scheme is valid and remains in force for a period of 10 years from 20 September 2012 (the "Scheme Period") unless terminated earlier by shareholders in general meeting. The purpose of Share Option Scheme is to enable the Board to grant share options to the Eligible Person as defined in Share Option Scheme including, among others, the directors, employee or proposed employee, consultants or advisers of or to the Company or its subsidiaries or any entity in which the Group holds an equity interest, as incentives or rewards for their contribution or potential contribution to the development and growth of the Group. The provisions of Share Option Scheme comply with the requirements of Chapter 17 of the Rules Governing the Listing of Securities on the Stock Exchange (the "Listing Rules").

Pursuant to Share Option Scheme, the offer for grant of options (“Offer”) must be accepted within 30 days inclusive of the day on which such offer was made, with a payment of HK\$1.00 as consideration for the grant. The exercise price of the share option is to be determined by the Board provided always that it shall be at least the higher of (i) the closing price of the shares as stated in the daily quotations sheet issued by the Stock Exchange for the date of offer of grant, which must be a business day; and (ii) the average closing price of the shares as stated in the daily quotations sheets issued by the Stock Exchange for the five business days immediately preceding the date of offer of grant provided that the option price per share shall in no event be less than the nominal amount of one share. The share options are exercisable at any time during a period as the Board may determine in granting the share options but in any event shall not exceed 10 years from the date of Offer, subject to the terms and conditions of Share Option Scheme and any conditions of grant as may be stipulated by the Board.

The aggregate number of shares which may be issued upon exercise of all outstanding options granted and yet to be exercised under Share Option Scheme and any other schemes shall not exceed 30% of the issued share capital of the Company from time to time. The maximum number of shares issuable upon exercise of all options to be granted Share Option Scheme and any other schemes as from the commencement of the Scheme Period must not, in aggregate, exceed 10% of the shares in issue as at 20 September 2012 (the “Scheme Mandate Limit”). The Scheme Mandate Limit may be refreshed at any time by obtaining approval of the shareholders in general meeting provided that the new limit under the refreshed Scheme Mandate Limit must not exceed 10% of the issued share capital of the Company at the date of the shareholders’ approval. The maximum number of shares issued and to be issued upon exercise of the options granted under Share Option Scheme and any other schemes to any of the Eligible Person (including cancelled, exercised and outstanding options) in any 12-month period up to the date of grant shall not exceed 1% of issued share capital of the Company unless shareholders’ approval is obtained under the terms of Share Option Scheme.

On 19 October 2015, the Company granted a total of 122,000,000 share options to two executive directors of the Company and other management staff of the Group under Share Option Scheme, representing about 4.33% of the issued share capital as at the date immediately before share options were granted. The exercise price was HK\$1.98. The exercisable period was from 19 October 2015 to 18 October 2018. During the year ended 31 December 2016, a total of 15,000,000 share options were exercised by one of management staff of the Group who was not a Director of the Company. As a result, a total of 15,000,000 ordinary shares of the Company was issued on 8 June 2016.

On 15 April 2016, the Company granted 122,000,000 share options to Mr. Qu Jiguang, the Chairman and the CEO of the Company, under Share Option Scheme, representing about 4.31% of the issued share capital as at the date immediately before share options were granted. The exercise price was HK\$2.58. The exercisable period was from 15 April 2016 to 14 April 2021. Such grant of share options was approved by the independent shareholders at the annual general meeting held on 27 May 2016.

The refreshment of Scheme Mandate Limit was approved at the annual general meeting held on 27 May 2016. Upon such approval, the Directors were authorised to grant share options to subscribe up to 10% of the issued share capital as at the date of such approval. Pursuant to the Listing Rules and the Share Option Scheme, share options previously granted under the Share Option Scheme (including those outstanding, cancelled, lapsed in accordance with the Share Option Scheme or exercised share options) will not be counted for purpose of calculating the Scheme Mandate Limit as refreshed. The limit on the number of shares which may be issued upon exercise of all outstanding share options granted and yet to be exercised under the Share Option Scheme and any other schemes of the Company must not exceed 30% of the shares in issue from time to time. No share options may be granted under the Share Option Scheme and any other schemes of the Company if this will result in the limit being exceeded.

No share option has been granted, exercised or lapsed for the six months ended 30 June 2017.

The movement of the total number of share options outstanding is shown as follows:

	Six months ended 30 June 2017	Year ended 31 December 2016
Outstanding at the beginning of the period/year	229,000,000	122,000,000
Granted during the period/year	—	122,000,000
Exercised during the period/year	—	(15,000,000)
Lapsed during the period/year	—	—
Outstanding and exercisable at the end of the period/year	229,000,000	229,000,000

As at 30 June 2017, the share options granted under Share Option Scheme and remained outstanding had an weighted average exercise price of approximately HK\$2.30 (31 December 2016: HK\$2.30) and a remaining contractual life of approximately 2.63 years (31 December 2016: 3.13 years).

The details of share options movements during the six months ended 30 June 2017 are shown as follows:

(i) Directors of the Company

Name of Director	Date of grant	Exercise price per share	Exercisable period	Number of share options			
				Outstanding at 1 Jan 2017	Granted during the period	Exercised during the period	Outstanding at 30 Jun 2017
Mr. Qu Jiguang	15 Apr 2016	HK\$2.58	15 Apr 2016 — 14 Apr 2021	122,000,000	—	—	122,000,000
Mr. Wang Xianjun	19 Oct 2015	HK\$1.98	19 Oct 2015 — 18 Oct 2018	24,416,000	—	—	24,416,000
Mr. Su Xuejun	19 Oct 2015	HK\$1.98	19 Oct 2015 — 18 Oct 2018	24,416,000	—	—	24,416,000
				170,832,000	—	—	170,832,000

(ii) Employees (other than directors of the Company)

Date of grant	Exercise price per share	Exercisable period	Number of share options			
			Outstanding at 1 Jan 2017	Granted during the period	Exercised during the period	Outstanding at 30 Jun 2017
19 Oct 2015	HK\$1.98	19 Oct 2015 — 18 Oct 2018	58,168,000	—	—	58,168,000
			58,168,000	—	—	58,168,000

Assuming that all share options outstanding as at 30 June 2017 are exercised, the Company will receive proceeds of HK\$526,620,000.

DIRECTORS' AND CHIEF EXECUTIVES' INTERESTS IN THE SHARES

As at 30 June 2017, the interests of the Directors in the share capital of the Company and its associated corporations (within the meaning of Part XV of the Securities and Futures Ordinance ("SFO")) as recorded in the register required to be kept by the Company pursuant to section 352 of the SFO, or as otherwise notified to the Company and the Stock Exchange pursuant to the Model Code for Securities Transactions by Directors of Listed Issuers ("Model Code") as set out in Appendix 10 to the Listing Rules once the shares are listed, were as follows:

Name of Director	Capacity	Long/short position	Number of shares and underlying shares held	Approximate percentage of the issued share capital of the Company
Mr. Qu Jiguang	Beneficial owner (Note 1)	Long	122,000,000	4.30%
	Beneficial owner	Long	155,746,000	5.48%
	Interest in a controlled corporation (Note 2)	Long	733,856,000	25.84%
Mr. Wang Xianjun	Beneficial owner (Note 3)	Long	24,416,000	0.86%
Mr. Su Xuejun	Beneficial owner (Note 3)	Long	24,416,000	0.86%

Notes:

- These shares represent the underlying interest in shares of the Company pursuant to share options granted to Mr. Qu Jiguang on 15 April 2016 under the Share Option Scheme.
- These shares were registered in the name of and beneficially owned by China Pharmaceutical Company Limited ("CPCL"). CPCL is held as to 72.93% by Mr. Qu Jiguang and as to 27.07% by 39 other shareholders. By virtue of Part XV of the SFO, Mr. Qu Jiguang is deemed to be interested in the shares held by CPCL.
- These shares represent the underlying interest in shares of the Company pursuant to share options granted, among others, to Mr. Wang Xianjun and Mr. Su Xuejun on 19 October 2015 under the Share Option Scheme.

Save as disclosed above, as at 30 June 2017, none of the Directors or chief executives of the Company had an interest or short position in the shares, underlying shares or debentures of the Company or any of its associated corporations (within the meaning of Part XV of the SFO) which were required (a) to be notified to the Company or the Stock Exchange pursuant to section 352 of the SFO, to be entered in the register referred to therein, or (b) pursuant to the Model Code to be notified to the Company and the Stock Exchange.

DIRECTORS' RIGHTS TO ACQUIRE SHARES AND DEBENTURES

Save as disclosed under the sections headed "Directors' and chief executives' interests in the shares" and "Share option scheme", at no time during the six months ended 30 June 2017 were rights to acquire benefits by means of the acquisition of shares or debentures of the Company granted to any Directors or their respective spouse or minor children, or were any such rights exercised by them; or was the Company or any of its subsidiaries a party to any arrangement to enable the Directors of the Company to acquire such rights in any other body corporate.

SUBSTANTIAL SHAREHOLDERS' AND OTHER PERSON'S INTERESTS IN THE SHARES

As at 30 June 2017, the register of substantial shareholders required to be kept by the Company under section 336 of the SFO shows that the Company had been notified of the following interests, being 5% or more in the issued share capital and underlying shares of the Company.

Name of Shareholder	Capacity	Long/short position	Number of shares and underlying shares held	Approximate percentage of the issued share capital of the Company
Mr. Qu Jiguang	Beneficial owner (Note 1)	Long	122,000,000	4.30%
	Beneficial owner	Long	155,746,000	5.48%
	Interest in a controlled corporation (Note 2)	Long	733,856,000	25.84%
CPL (Note 2)	Beneficial owner	Long	733,856,000	25.84%

Name of Shareholder	Capacity	Long/short position	Number of shares and underlying shares held	Approximate percentage of the issued share capital of the Company
Sichuan Kelun Pharmaceutical Co., Ltd (四川科倫藥業股份有限公司)	Beneficial owner	Long	56,150,000	1.98%
	Interest in a controlled corporation (Note 3)	Long	426,688,000	15.02%
Kelun International Development Co., Ltd (科倫國際發展有限公司) (Note 3)	Beneficial owner	Long	426,688,000	15.02%
UBS Group AG (Note 4)	Interest in a controlled corporation	Long	172,859,409	6.09%
	Person having a security interest in shares	Long	3,368,685	0.12%
	Interest in a controlled corporation	Short	2,252,000	0.08%

Notes:

- These shares represent the underlying interest in shares of the Company pursuant to share options granted to Mr. Qu Jiguang on 15 April 2016 under the Share Option Scheme.
- These shares were registered in the name of and beneficially owned by CPCL. CPCL is held as to 72.93% by Mr. Qu Jiguang and as to 27.07% by 39 other shareholders. By virtue of Part XV of the SFO, Mr. Qu Jiguang is deemed to be interested in the shares held by CPCL.
- These shares were registered in the name of and beneficially owned by Kelun International Development Co., Ltd (科倫國際發展有限公司). Kelun International Development Co., Ltd (科倫國際發展有限公司) is held as to 100% by Sichuan Kelun Pharmaceutical Co., Ltd (四川科倫藥業股份有限公司).
- Among the aggregate interests of UBS Group AG in the Company, 1,752,000 (short position) were held through cash settled derivatives (off exchange).

MODEL CODE FOR SECURITIES TRANSACTIONS BY DIRECTORS

The Company has adopted the Model Code for Securities Transactions by Directors of Listed Issuers as set out in Appendix 10 to the Listing Rules (the “Model Code”). Having made specific enquiry with all Directors, the Directors confirmed that they had complied with the required standard set out in the Model Code during the six months ended 30 June 2017.

CORPORATE GOVERNANCE PRACTICES

The Board is committed to maintaining a high standard of corporate governance. The Board believes that good corporate governance practices are essential for the growth of the Group and for safeguarding and maximizing shareholders’ interests.

The Company has adopted the Corporate Governance Code (the “CG Code”) contained in Appendix 14 of the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited (the “Listing Rules”). During the six months ended 30 June 2017, the Company has complied with all applicable provisions of CG Code with deviation from code provision A.2.1 as set out below.

Code provision A.2.1 of the CG Code stipulates that the roles of chairman and chief executive officer should be separate and should not be performed by the same individual.

The Board appointed Mr. Qu Jiguang as the Chairman, who was responsible for the leadership and effective running of the Board. Mr. Qu Jiguang has also assumed the role as the chief executive officer of the Company, who was delegated with the responsibilities to lead the management implementing the business strategies of the Group. The Company believes that vesting both roles in Mr. Qu Jiguang will allow for more effective planning and execution of business strategies. As all major decisions are made in consultation with members of the Board, the Company believes that there is adequate balance of power and authority in place.

INDEPENDENT REVIEW OF AUDITORS

The interim financial report for the six months ended 30 June 2017 is unaudited, but has been reviewed by KPMG, in accordance with Hong Kong Standard on Review Engagements 2410 “Review of Interim Financial Information Performed by the Independent Auditor of the Entity” issued by the Hong Kong Institute of Certified Public Accountants, whose unmodified review report is included in the interim report.

AUDIT COMMITTEE

The Audit Committee has reviewed and approved the interim financial information contained in the interim report for the six months ended 30 June 2017.

CLOSURE OF REGISTER OF MEMBERS

The register of members of the Company will be closed from Monday, 11 September 2017 to Wednesday, 13 September 2017 (both days inclusive), during which period, no transfer of shares will be registered.

In order to qualify for the interim dividend, all transfer documents, accompanied by the relevant share certificate(s) must be lodged with the Company’s branch share registrar and transfer office of the Company in Hong Kong, Computershare Hong Kong Investor Services Limited at 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong by no later than 4:30 p.m., Friday, 8 September 2017.

On behalf of the Board

Qu Jiguang

Chairman

Hong Kong, 23 August 2017

Review report to the board of directors of SSY Group Limited

(Incorporated in Cayman Islands with limited liability)

INTRODUCTION

We have reviewed the interim financial report set out on pages 28 to 48 which comprises the consolidated statement of financial position of SSY Group Limited (the “Company”) as of 30 June 2017 and the related consolidated statement of profit or loss and other comprehensive income, consolidated statement of changes in equity and condensed consolidated cash flow statement for the six months period then ended and explanatory notes. The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited require the preparation of an interim financial report to be in compliance with the relevant provisions thereof and Hong Kong Accounting Standard 34, *Interim financial reporting*, issued by the Hong Kong Institute of Certified Public Accountants. The directors are responsible for the preparation and presentation of the interim financial report in accordance with Hong Kong Accounting Standard 34.

Our responsibility is to form a conclusion, based on our review, on the interim financial report and to report our conclusion solely to you, as a body, in accordance with our agreed terms of engagement, and for no other purpose. We do not assume responsibility towards or accept liability to any other person for the contents of this report.

SCOPE OF REVIEW

We conducted our review in accordance with Hong Kong Standard on Review Engagements 2410, *Review of interim financial information performed by the independent auditor of the entity*, issued by the Hong Kong Institute of Certified Public Accountants. A review of the interim financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Hong Kong Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly we do not express an audit opinion.

CONCLUSION

Based on our review, nothing has come to our attention that causes us to believe that the interim financial report as at 30 June 2017 is not prepared, in all material respects, in accordance with Hong Kong Accounting Standard 34, *Interim financial reporting*.

KPMG

Certified Public Accountants

8th Floor, Prince's Building
10 Chater Road
Central, Hong Kong

23 August 2017

CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

for the six months ended 30 June 2017 (unaudited)

(Expressed in Hong Kong dollars)

	Note	Six months ended 30 June	
		2017 HK\$'000	2016 HK\$'000
Revenue	4	1,325,337	1,109,112
Cost of sales		(597,206)	(559,039)
Gross profit		728,131	550,073
Other net income		2,511	46,779
Selling and distribution costs		(233,594)	(157,257)
General and administrative expenses		(121,755)	(150,209)
Profit from operations		375,293	289,386
Finance income		1,337	1,090
Finance costs		(23,175)	(27,286)
Finance costs – net	5(a)	(21,838)	(26,196)
Share of losses of a joint venture		—	(1,189)
Profit before taxation	5	353,455	262,001
Income tax	6	(65,630)	(51,567)
Profit for the period		287,825	210,434
Other comprehensive income for the period, net of tax			
Items that may be reclassified subsequently to profit or loss:			
Exchange differences on translation to presentation currency		109,760	(79,557)
Other comprehensive income for the period		109,760	(79,557)
Total comprehensive income for the period		397,585	130,877

CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

for the six months ended 30 June 2017 (unaudited)

(Expressed in Hong Kong dollars)

	Note	Six months ended 30 June	
		2017 HK\$'000	2016 HK\$'000
Profit attributable to:			
Equity shareholders of the Company		288,016	210,428
Non-controlling interests		(191)	6
Profit for the period		287,825	210,434
Total comprehensive income attributable to:			
Equity shareholders of the Company		397,576	130,884
Non-controlling interests		9	(7)
Total comprehensive income for the period		397,585	130,877
Earnings per share	7		
— Basic		HK\$0.1014	HK\$0.0747
— Diluted		HK\$0.0999	HK\$0.0742

The notes on pages 36 to 48 form part of this interim financial report. Details of dividends payable to equity shareholders of the Company are set out in note 13(a).

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

at 30 June 2017 (unaudited)

(Expressed in Hong Kong dollars)

	Note	At 30 June 2017		At 31 December 2016	
		HK\$'000	HK\$'000	HK\$'000	HK\$'000
Non-current assets					
Property, plant and equipment	8		2,414,149		2,393,091
Land use rights	8		253,413		248,771
Intangible assets	8		445,683		418,509
Deferred tax assets			2,906		3,053
Long-term prepayments and receivables	9		41,478		1,118
			3,157,629		3,064,542
Current assets					
Inventories			326,347		278,228
Trade and bills receivables	10		1,016,064		857,387
Prepayments, deposits and other receivables			95,287		88,680
Pledged bank deposits and time deposits			32,339		8,201
Cash and cash equivalents			469,950		447,036
			1,939,987		1,679,532
Current liabilities					
Borrowings	11		925,632		633,126
Trade payables	12		157,367		173,746
Advanced receipts from customers			11,346		15,530
Accruals and other payables			234,586		250,033
Income tax payable			32,713		23,120
			1,361,644		1,095,555
Net current assets			578,343		583,977
Total assets less current liabilities			3,735,972		3,648,519

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

at 30 June 2017 (unaudited)

(Expressed in Hong Kong dollars)

	Note	At 30 June 2017		At 31 December 2016	
		HK\$'000	HK\$'000	HK\$'000	HK\$'000
Non-current liabilities					
Borrowings	11	720,876		934,737	
Deferred tax liabilities		26,265		26,810	
Deferred revenue		2,091		2,550	
			749,232		964,097
NET ASSETS			2,986,740		2,684,422
CAPITAL AND RESERVES	13				
Share capital			63,606		63,700
Reserves			2,915,177		2,612,774
Total equity attributable to equity shareholders of the Company			2,978,783		2,676,474
Non-controlling interests			7,957		7,948
TOTAL EQUITY			2,986,740		2,684,422

Approved and authorised for issue by the board of directors on 23 August 2017.

Qu Jiguang
Director

Wang Xianjun
Director

The notes on pages 36 to 48 form part of this interim financial report.

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

for the six months ended 30 June 2017 (unaudited)

(Expressed in Hong Kong dollars)

	Attributable to equity shareholders of the Company										
	Note	Share capital HK\$'000	Share premium HK\$'000	Capital reserve HK\$'000	Statutory reserve HK\$'000	Share-based payment reserve HK\$'000	Currency translation differences HK\$'000	Retained earnings HK\$'000	Total HK\$'000	Non-controlling interests HK\$'000	Total equity HK\$'000
Balance at 1 January 2016		62,851	493,065	176,819	223,997	39,431	(30,132)	1,428,485	2,394,516	663	2,395,179
Changes in equity for the six months ended 30 June 2016:											
Profit for the period		—	—	—	—	—	—	210,428	210,428	6	210,434
Other comprehensive income		—	—	—	—	—	(79,544)	—	(79,544)	(13)	(79,557)
Total comprehensive income		—	—	—	—	—	(79,544)	210,428	130,884	(7)	130,877
Purchase and cancellation of own shares	13(b)	(20)	(1,915)	—	—	—	—	—	(1,935)	—	(1,935)
Grant of share options	13(c)	—	—	—	—	26,686	—	—	26,686	—	26,686
Shares issued under share option scheme	13(c)	300	34,248	—	—	(4,848)	—	—	29,700	—	29,700
Issue of new shares	13(d)	569	68,502	—	—	—	—	—	69,071	—	69,071
Acquisition of additional interests in a subsidiary		—	—	—	—	—	—	—	—	(105)	(105)
Balance at 30 June 2016 and 1 July 2016		63,700	593,900	176,819	223,997	61,269	(109,676)	1,638,913	2,648,922	551	2,649,473
Changes in equity for the six months ended 31 December 2016:											
Profit for the period		—	—	—	—	—	—	279,107	279,107	700	279,807
Other comprehensive income		—	—	—	—	—	(150,843)	—	(150,843)	13	(150,830)
Total comprehensive income		—	—	—	—	—	(150,843)	279,107	128,264	713	128,977
Purchase and cancellation of own shares		—	(18,180)	(11,417)	—	—	—	—	(29,597)	—	(29,597)
Acquisition of a subsidiary		—	—	—	—	—	—	—	—	6,684	6,684
Dividends paid to equity shareholders of the Company		—	(71,115)	—	—	—	—	—	(71,115)	—	(71,115)
Transfer to statutory reserve		—	—	—	4,119	—	—	(4,119)	—	—	—
Balance at 31 December 2016		63,700	504,605	165,402	228,116	61,269	(260,519)	1,913,901	2,676,474	7,948	2,684,422

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

for the six months ended 30 June 2017 (unaudited)

(Expressed in Hong Kong dollars)

	Attributable to equity shareholders of the Company										
	Note	Share capital HK\$'000	Share premium HK\$'000	Capital reserve HK\$'000	Statutory reserve HK\$'000	Share-based payment reserve HK\$'000	Currency translation differences HK\$'000	Retained earnings HK\$'000	Total HK\$'000	Non-controlling interests HK\$'000	Total equity HK\$'000
Balance at 1 January 2017		63,700	504,605	165,402	228,116	61,269	(260,519)	1,913,901	2,676,474	7,948	2,684,422
Changes in equity for the six months ended 30 June 2017:											
Profit for the period		—	—	—	—	—	288,016	288,016	(191)	287,825	
Other comprehensive income		—	—	—	—	109,560	—	109,560	200	109,760	
Total comprehensive income		—	—	—	—	109,560	288,016	397,576	9	397,585	
Dividends paid to equity shareholders of the Company	13(a)	—	(85,200)	—	—	—	—	(85,200)	—	(85,200)	
Cancellation of shares	13(b)	(94)	(21,293)	11,320	—	—	—	(10,067)	—	(10,067)	
Balance at 30 June 2017		63,606	398,112	176,722	228,116	61,269	(150,959)	2,201,917	2,978,783	7,957	2,986,740

The notes on pages 36 to 48 form part of this interim financial report.

CONDENSED CONSOLIDATED CASH FLOW STATEMENT

for the six months ended 30 June 2017 (unaudited)

(Expressed in Hong Kong dollars)

	Six months ended 30 June	
	2017 HK\$'000	2016 HK\$'000
Operating activities		
Cash generated from operations	300,379	169,250
Interest paid	(30,150)	(26,044)
Income tax paid	(57,870)	(43,704)
Net cash generated from operating activities	212,359	99,502
Investing activities		
Purchase of property, plant and equipment	(86,906)	(45,612)
Purchase of intangible assets	(60,456)	(12,002)
Proceeds from disposals of property, plant and equipment	2,674	9,986
Payments for acquisition of a subsidiary	—	(14,612)
Other cash flows arising from investing activities	(21,968)	985
Net cash used in investing activities	(166,656)	(61,255)

CONDENSED CONSOLIDATED CASH FLOW STATEMENT

for the six months ended 30 June 2017 (unaudited)

(Expressed in Hong Kong dollars)

	Six months ended 30 June	
	2017 HK\$'000	2016 HK\$'000
Financing activities		
Proceeds from exercise of share options	—	29,700
Proceeds from borrowings	406,442	508,159
Repayments of borrowings	(354,880)	(534,687)
Dividends paid to equity shareholders of the Company	(85,200)	—
Other cash flows arising from financing activities	(1,438)	(1,935)
Net cash (used in)/generated from financing activities	(35,076)	1,237
Net increase in cash and cash equivalents	10,627	39,484
Cash and cash equivalents at 1 January	447,036	338,964
Effect of foreign exchanges rates changes	12,287	(5,125)
Cash and cash equivalents at 30 June	469,950	373,323

The notes on pages 36 to 48 form part of this interim financial report.

NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT

(Expressed in Hong Kong dollars unless otherwise indicated)

1. GENERAL INFORMATION

SSY Group Limited (the “Company”) and its subsidiaries (together, the “Group”) are engaged in the research, development, manufacturing and selling of a wide range of finished medicines, bulk pharmaceutical products and medical materials. The Group has manufacturing plants in Hebei Province and Jiangsu Province, the People’s Republic of China (the “PRC”), and sells to customers mainly in the PRC.

The Company is an exempted company with limited liability established under the Companies Law, Cap.22 (Law 3 of 1961, as combined and revised) of Cayman Islands. The address of the Company’s registered office is Cricket Square, Hutchins Drive, P.O. Box 2681, Grand Cayman KY1-1111, Cayman Islands.

The Company’s shares have been listed on The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) since 20 December 2005.

2. BASIS OF PREPARATION

This interim financial report has been prepared in accordance with the applicable disclosure provisions of the Rules Governing the Listing of Securities on the Stock Exchange, including compliance with Hong Kong Accounting Standard (“HKAS”) 34, *Interim financial reporting*, issued by the Hong Kong Institute of Certified Public Accountants (“HKICPA”). It was authorised for issue on 23 August 2017.

The interim financial report has been prepared in accordance with the same accounting policies adopted in the 2016 annual financial statements, except for the accounting policy changes that are expected to be reflected in the 2017 annual financial statements. Details of any changes in accounting policies are set out in note 3.

The preparation of an interim financial report in conformity with HKAS 34 requires management to make judgments, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, income and expenses on a year to date basis. Actual results may differ from these estimates.

2. BASIS OF PREPARATION *(continued)*

The interim financial report contains condensed consolidated financial statements and selected explanatory notes. The notes include an explanation of events and transactions that are significant to an understanding of the changes in financial position and performance of the Group since the 2016 annual financial statements. The condensed consolidated interim financial statements and notes thereon do not include all of the information required for full set of financial statements prepared in accordance with Hong Kong Financial Reporting Standards (“HKFRSs”).

The interim financial report is unaudited, but has been reviewed by KPMG in accordance with Hong Kong Standard on Review Engagements 2410, *Review of interim financial information performed by the independent auditor of the entity*, issued by the HKICPA. KPMG’s independent review report to the Board of Directors is included on page 26 and 27.

The financial information relating to the financial year ended 31 December 2016 that is included in the interim financial report as comparative information does not constitute the Company’s statutory annual consolidated financial statements for that financial year but is derived from those financial statements. Statutory financial statements for the year ended 31 December 2016 are available from the Company’s registered office. The auditors have expressed an unqualified opinion on those financial statements in their report dated 29 March 2017.

3. CHANGES IN ACCOUNTING POLICIES

The HKICPA has issued several amendments to HKFRSs that are first effective for the current accounting period of the Group. None of these developments has had a material effect on how the Group’s results and financial position for the current or prior periods have been prepared or presented in this interim financial report.

The Group has not applied any new standard or interpretation that is not yet effective for the current accounting period.

4. SEGMENT REPORTING

The Group manages its businesses by divisions, which are organised by a mixture of both business lines and geography. In a manner consistent with the way in which information is reported internally to the Group's most senior executive management for the purposes of resource allocation and performance assessment, the Group has identified two reportable segments, namely intravenous infusion solution and others and medical materials. No operating segments have been aggregated to form the following reportable segments.

Information regarding the Group's reportable segments as provided to the Group's most senior executive management for the purposes of resource allocation and assessment of segment performance for the period is set out below:

	Six months ended 30 June 2017			
	Intravenous infusion solution and others HK\$'000	Medical materials HK\$'000	Unallocated HK\$'000	Total HK\$'000
Revenue from external customers	1,261,165	64,172	—	1,325,337
Inter-segment revenue	—	68,596	—	68,596
Reportable segment revenue	1,261,165	132,768	—	1,393,933
Operating profit/(loss)/ segment results	378,005	5,645	(8,357)	375,293
Finance income	1,171	166	—	1,337
Finance costs	(18,481)	(1,295)	(3,399)	(23,175)
Profit/(loss) before income tax	360,695	4,516	(11,756)	353,455
Income tax	(62,700)	(2,930)	—	(65,630)
Reportable segment profit/(loss) for the period	297,995	1,586	(11,756)	287,825

4. SEGMENT REPORTING (continued)

	Six months ended 30 June 2016			
	Intravenous infusion solution and others <i>HK\$'000</i>	Medical materials <i>HK\$'000</i>	Unallocated <i>HK\$'000</i>	Total <i>HK\$'000</i>
Revenue from external customers	1,036,716	72,396	—	1,109,112
Inter-segment revenue	—	40,580	—	40,580
Reportable segment revenue	1,036,716	112,976	—	1,149,692
Operating profit/(loss)/segment results	313,104	9,971	(34,878)	288,197
Finance income	1,073	17	—	1,090
Finance costs	(26,342)	(944)	—	(27,286)
Profit/(loss) before income tax	287,835	9,044	(34,878)	262,001
Income tax	(50,129)	(1,438)	—	(51,567)
Reportable segment profit/(loss) for the period	237,706	7,606	(34,878)	210,434

	At 30 June 2017			
	Intravenous infusion solution and others <i>HK\$'000</i>	Medical materials <i>HK\$'000</i>	Unallocated <i>HK\$'000</i>	Total <i>HK\$'000</i>
Reportable segment assets	4,712,818	340,385	44,413	5,097,616
Reportable segment liabilities	1,374,474	100,897	635,505	2,110,876

4. SEGMENT REPORTING (continued)

	At 31 December 2016			
	Intravenous infusion solution and others HK\$'000	Medical materials HK\$'000	Unallocated HK\$'000	Total HK\$'000
Reportable segment assets	4,398,839	331,116	14,119	4,744,074
Reportable segment liabilities	1,261,682	99,002	698,968	2,059,652

5. PROFIT BEFORE TAXATION

Profit before taxation is arrived at after charging/(crediting):

	Six months ended 30 June	
	2017 HK\$'000	2016 HK\$'000
(a) Finance income and costs		
Financial income:		
— Interest income on bank deposits	(1,337)	(1,090)
Financial costs:		
— Interest expenses of borrowings	23,054	26,984
— Other bank charges	119	1,355
— Net foreign exchange loss	2	2,052
	23,175	30,391
Less: Interest expenses capitalised into qualifying assets*	—	(3,105)
Financial costs	23,175	27,286
Financial costs — net	21,838	26,196

* During the six months ended 30 June 2016, the borrowing costs have been capitalised at a rate of 5.24% per annum.

5. PROFIT BEFORE TAXATION (continued)

	Six months ended 30 June	
	2017	2016
	HK\$'000	HK\$'000
(b) Other items		
Loss/(gain) on disposal of property, plant and equipment	273	(1,091)
Government grants	(2,784)	(45,688)
Depreciation of property, plant and equipment	116,523	111,186
Amortisation of intangible assets	6,574	4,887
Amortisation of land use rights	2,934	3,173
Research and development costs	27,829	21,588

6. INCOME TAX

	Six months ended 30 June	
	2017	2016
	HK\$'000	HK\$'000
Current tax — PRC corporate income tax ("CIT")	66,573	49,755
Deferred taxation	(943)	1,812
	65,630	51,567

All subsidiaries of the Company established and operated in PRC are subject to the PRC CIT at an applicable rate of 25%.

Shijiazhuang No. 4 Pharmaceutical Co., Ltd., Jiangsu Best New Medical Material Co., Ltd. ("Jiangsu Best") and Hebei Guolong Pharmaceutical Co., Ltd. have been certified as High and New Technology Enterprises in 2015, 2014 and 2014, respectively. According to the tax incentives rules of the CIT Law of the People's Republic of China (the "CIT Law") for High and New Technology Enterprises, these entities are subject to preferential income tax rate of 15% for three years.

6. INCOME TAX *(continued)*

The CIT law and its relevant regulations also impose a withholding tax at 10% on the foreign investors with respect to dividend distributions made out of the PRC entities from earnings accumulated from 1 January 2008, unless the foreign investors meet certain requirements specified in the relevant tax regulations in the PRC and accordingly are entitled to a preferential rate of 5%. Deferred tax liabilities have been provided for in this regard based on the expected dividends to be distributed from the Group's PRC subsidiaries in the foreseeable future in respect of the profits generated since 1 January 2008.

Taxation for other entities of the Group is charged at their respective applicable income tax rates ruling in the relevant jurisdictions.

7. EARNINGS PER SHARE

(a) Basic earnings per share

The calculation of basic earnings per share is based on the profit attributable to ordinary equity shareholders of the Company of HK\$288,016,000 for the six months ended 30 June 2017 (six months ended 30 June 2016: HK\$210,428,000) and the weighted average of 2,839,915,000 ordinary shares (six months ended 30 June 2016: 2,815,760,000 ordinary shares) in issue during the interim period.

(b) Diluted earnings per share

The calculation of diluted earnings per share is based on the profit attributable to equity shareholders of the Company of HK\$288,016,000 for the six months ended 30 June 2017 (six months ended 30 June 2016: HK\$210,428,000) and the weighted average shares of 2,883,286,000 shares for the six months ended 30 June 2017 (six months ended 30 June 2016: 2,836,652,000 ordinary shares) after adjusting for the effects of dilutive potential ordinary shares under the Company's share option scheme, calculated as follows:

(i) Weighted average number of ordinary shares (diluted)

	Six months ended 30 June	
	2017	2016
	'000	'000
Weighted average number of ordinary shares at 30 June (basic)	2,839,915	2,815,760
Effect of deemed issue of shares under the Company's share option scheme	43,371	20,892
Weighted average number of ordinary shares at 30 June (diluted)	2,883,286	2,836,652

8. LAND USE RIGHT, PROPERTY, PLANT AND EQUIPMENT AND INTANGIBLE ASSETS

During the six months ended 30 June 2017, the Group acquired items of property, plant and equipment and internally generated research and development costs with costs of HK\$69,224,000 and HK\$20,876,000 respectively (six months ended 30 June 2016: HK\$47,856,000 and HK\$12,002,000 respectively).

Items of plant and equipment with a carrying amount of HK\$4,715,000 were disposed of during the six months ended 30 June 2017 (six months ended 30 June 2016: HK\$15,062,000), resulting in a loss on disposal of HK\$273,000 (six months ended 30 June 2016: a gain of HK\$1,091,000).

As at 30 June 2017, the Group's land use rights and property, plant and equipment with carrying amount of HK\$19,552,000 (31 December 2016: HK\$19,241,000) and HK\$28,041,000 (31 December 2016: HK\$28,979,000) respectively were pledged as collateral for the Group's bank borrowings (note 11).

9. LONG-TERM PREPAYMENTS AND RECEIVABLES

In April 2017, the Group entered into a technologies transfer agreement (the "Technologies Transfer Agreement") with a third party, pursuant to which, the Group agreed to acquire certain pharmaceutical technologies at a consideration of RMB35,000,000. As at 30 June 2017, the Group had prepaid RMB35,000,000 (equivalent to HK\$40,326,000) to an escrow account in accordance with the Technologies Transfer Agreement and the transfer of said technologies was yet to be completed.

10. TRADE AND BILLS RECEIVABLES

As of the end of the reporting period, the ageing analysis of trade debtors and bills receivables, based on the invoice date (or date of revenue recognition, if earlier) and net of allowance for doubtful debts, is as follows:

	30 June 2017 HK\$'000	31 December 2016 HK\$'000
Within 3 months	863,110	719,969
4 to 6 months	114,890	109,746
7 to 12 months	40,250	31,045
1 to 2 years	2,084	1,017
	1,020,334	861,777
Less: Allowance for doubtful debts	(4,270)	(4,390)
	1,016,064	857,387

11. BORROWINGS

As of the end of the reporting period, the borrowings were repayable as follows:

	30 June 2017 HK\$'000	31 December 2016 HK\$'000
Within 1 year or on demand	925,632	633,126
After 1 year but within 2 years	662,115	866,543
After 2 years but within 5 years	58,761	68,194
	720,876	934,737
	1,646,508	1,567,863

As of the end of the reporting period, the borrowings were secured as follows:

	30 June 2017 HK\$'000	31 December 2016 HK\$'000
Bank borrowings		
— secured	104,848	110,675
— unsecured	1,541,660	1,457,188
	1,646,508	1,567,863

As at 30 June 2017, certain of the Group's borrowings were secured by the Group's land use rights with carrying amount of HK\$19,552,000 (31 December 2016: HK\$19,241,000) and property, plant and equipment with carrying amount of HK\$28,041,000 (31 December 2016: HK\$28,979,000).

The Group's bank facilities of HK\$894,660,000 (31 December 2016: HK\$875,897,000) is subject to the fulfilment of covenants relating to certain specific performance requirements on the Group. If the Group were to breach the covenants, drawn down would become payable on demand. The Group regularly monitors its compliance with covenants. As at 30 June 2017, none of the covenants relating to drawn down facilities had been breached.

12. **TRADE PAYABLES**

As of the end of the reporting period, the ageing analysis of trade payables, based on the invoice date, is as follows:

	30 June 2017 HK\$'000	31 December 2016 HK\$'000
Within 3 months	137,245	157,751
4 to 6 months	12,217	9,761
7 to 12 months	6,086	3,490
1 to 3 years	1,121	1,917
More than 3 years	698	827
	157,367	173,746

13. **CAPITAL, RESERVES AND DIVIDENDS**

(a) **Dividends**

(i) *Dividends payable to equity shareholders attributable to the interim period*

	Six months ended 30 June	
	2017 HK\$'000	2016 HK\$'000
Interim dividend declared and paid after the interim period, of HK3.0 cents per share (30 June 2016: HK2.5 cents per share)	85,199	71,115

The interim dividend has not been recognised as a liability at the end of the reporting period.

13. CAPITAL, RESERVES AND DIVIDENDS *(continued)*

(a) Dividends *(continued)*

(ii) Dividends payable to equity shareholders attributable to the previous financial year, approved and paid during the interim period.

	Six months ended 30 June	
	2017 HK\$'000	2016 HK\$'000
Final dividend proposed after the end of the reporting period of HK3.0 cents per share (30 June 2016: nil)	85,200	—

(b) Cancellation of shares

In January 2017, 4,654,000 ordinary shares were cancelled in accordance with the Companies Law of the Cayman Islands, which were repurchased in December 2016 (six months ended 30 June 2016: 1,018,000 ordinary shares were repurchased and cancelled).

(c) Equity settled share-based transactions

During the six months ended 30 June 2017, no share options were granted or exercised.

During the six months ended 30 June 2016, (i) 122,000,000 share options were granted to Mr. Qu Jiguang at a consideration of HK\$1.00. Each option entitles the holder to subscribe for one ordinary share of the Company with an exercise price of HK\$2.58; and (ii) 15,000,000 share options were exercised by a management staff of the Group, who is not a director of the Company with an exercise price of HK\$1.98 for 15,000,000 ordinary shares in the Company at a total consideration of HK\$29,700,000.

(d) Shares issued upon acquisition of a subsidiary

On 11 April 2016, the Company issued 28,436,000 ordinary shares of the Company to the former owners of Jiangsu Best at the issue price of HK\$2.429 per share as part of the consideration in relation to the acquisition of 100% equity interests in Jiangsu Best.

Further details were respectively set out in the Company's announcements dated 1 September 2015, 29 December 2015, 31 March 2016 and 11 April 2016.

14. FAIR VALUE MEASUREMENT OF FINANCIAL INSTRUMENTS

The three-level fair value hierarchy of financial instruments as defined in HKFRS 13, *Fair value measurement*. The level into which a fair value measurement is classified is determined with reference to the observability and significance of the inputs used in the valuation technique as follows:

- Level 1 valuations: Fair value measured using only Level 1 inputs i.e. unadjusted quoted prices in active markets for identical assets or liabilities at the measurement date
- Level 2 valuations: Fair value measured using Level 2 inputs i.e. observable inputs which fail to meet Level 1, and not using significant unobservable inputs. Unobservable inputs are inputs for which market data are not available
- Level 3 valuations: Fair value measured using significant unobservable inputs

As at 30 June 2017, the Group did not have any assets or liabilities that were measured at fair value.

The carrying values of the Group's financial instruments carried at cost or amortised cost were not materially different from their fair values as at 30 June 2017.

For the six months ended 30 June 2017, there were no significant changes in the business or economic circumstances that affect the fair value of the Group's financial instruments. Moreover, there were no significant reclassifications of financial instruments.

15. CAPITAL COMMITMENTS OUTSTANDING NOT PROVIDED FOR

	30 June 2017 HK\$'000	31 December 2016 HK\$'000
Contracted for	84,750	54,478
Authorised but not contracted for	21,446	10,076
	106,196	64,554

16. MATERIAL RELATED PARTY TRANSACTIONS

(a) Key management personnel remuneration

	Six months ended 30 June	
	2017 HK\$'000	2016 <i>HK\$'000</i>
Salaries and other benefits	4,511	4,685
Equity-settled share-based payment expenses	—	26,686
	4,511	31,371

17. NON-ADJUSTING EVENTS AFTER THE REPORTING PERIOD

In July 2017, the Group entered into a facility agreement (the "Facility Agreement") with banks to refinance a loan with an outstanding principal amount of HK\$640,000,000, originally due in September 2018. The new loan is due in July 2020 and bears an interest which is linked to the Hong Kong interbank offered rate. Pursuant to the Facility Agreement, the banks also agreed to provide an additional facility of HK\$140,000,000 for general corporate funding requirements to the Group. No adjustments is required to be made to these financial statements as a result of this re-financing.